Redhill Biopharma Ltd. (NASDAQ:RDHL) has received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $27.33.

RDHL has been the topic of a number of analyst reports. Seaport Global Securities initiated coverage on Redhill Biopharma in a research note on Friday, October 6th. They set a “buy” rating and a $19.00 target price on the stock. Roth Capital reissued a “buy” rating and issued a $27.00 price objective on shares of Redhill Biopharma in a research note on Wednesday, October 4th. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Redhill Biopharma in a research note on Wednesday, October 4th. Zacks Investment Research raised Redhill Biopharma from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a research note on Tuesday, July 4th. Finally, UBS AG began coverage on Redhill Biopharma in a research note on Wednesday, September 13th. They issued a “reduce” rating on the stock.

Shares of Redhill Biopharma (NASDAQ:RDHL) opened at 8.97 on Tuesday. Redhill Biopharma has a 12 month low of $8.16 and a 12 month high of $12.65. The stock has a 50 day moving average price of $9.17 and a 200-day moving average price of $9.21. The company’s market capitalization is $153.95 million.

ILLEGAL ACTIVITY NOTICE: “Redhill Biopharma Ltd. (RDHL) Given Consensus Recommendation of “Buy” by Brokerages” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/31/redhill-biopharma-ltd-rdhl-given-consensus-recommendation-of-buy-by-brokerages.html.

A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in Redhill Biopharma by 144.1% in the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 36,600 shares in the last quarter. D.A. Davidson & CO. grew its stake in Redhill Biopharma by 10.0% in the second quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 4,000 shares in the last quarter. Jane Street Group LLC bought a new position in Redhill Biopharma in the first quarter worth approximately $276,000. Family Management Corp grew its stake in Redhill Biopharma by 51.5% in the second quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 8,750 shares in the last quarter. Finally, Oppenheimer & Co. Inc. grew its stake in Redhill Biopharma by 10.8% in the second quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 2,500 shares in the last quarter. 10.98% of the stock is currently owned by institutional investors.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.